A number of research firms have changed their ratings and price targets for Stemline Therapeutics (NASDAQ: STML):

  • 6/12/2018 – Stemline Therapeutics is now covered by analysts at Roth Capital. They set a “buy” rating and a $30.00 price target on the stock.
  • 6/8/2018 – Stemline Therapeutics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 6/6/2018 – Stemline Therapeutics was given a new $38.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 6/2/2018 – Stemline Therapeutics was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 5/29/2018 – Stemline Therapeutics had its price target raised by analysts at Wedbush from $20.00 to $22.00. They now have an “outperform” rating on the stock.
  • 5/22/2018 – Stemline Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “
  • 5/14/2018 – Stemline Therapeutics was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 5/10/2018 – Stemline Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 5/10/2018 – Stemline Therapeutics was given a new $38.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 5/8/2018 – Stemline Therapeutics was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 5/2/2018 – Stemline Therapeutics was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 5/1/2018 – Stemline Therapeutics was given a new $38.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.

NASDAQ STML traded down $0.20 on Thursday, hitting $17.70. 232,900 shares of the company were exchanged, compared to its average volume of 302,267. The firm has a market cap of $541.90 million and a PE ratio of -6.02. Stemline Therapeutics Inc has a 12 month low of $7.30 and a 12 month high of $20.55.

Stemline Therapeutics (NASDAQ:STML) last issued its earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.26). Stemline Therapeutics had a negative return on equity of 101.93% and a negative net margin of 4,689.63%. equities analysts anticipate that Stemline Therapeutics Inc will post -2.78 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of STML. Schwab Charles Investment Management Inc. boosted its stake in Stemline Therapeutics by 17.0% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 47,025 shares of the biopharmaceutical company’s stock worth $734,000 after acquiring an additional 6,825 shares in the last quarter. Raymond James Financial Services Advisors Inc. bought a new position in Stemline Therapeutics during the fourth quarter worth $189,000. Bank of New York Mellon Corp boosted its stake in Stemline Therapeutics by 23.1% during the fourth quarter. Bank of New York Mellon Corp now owns 100,813 shares of the biopharmaceutical company’s stock worth $1,573,000 after acquiring an additional 18,899 shares in the last quarter. BlackRock Inc. boosted its stake in Stemline Therapeutics by 6.3% during the fourth quarter. BlackRock Inc. now owns 1,406,181 shares of the biopharmaceutical company’s stock worth $21,936,000 after acquiring an additional 83,044 shares in the last quarter. Finally, Royce & Associates LP bought a new position in Stemline Therapeutics during the fourth quarter worth $106,000. 66.91% of the stock is currently owned by institutional investors and hedge funds.

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.